Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Announce Quarterly Sales of $32.52 Million

Equities research analysts predict that Aerie Pharmaceuticals, Inc. (NASDAQ:AERIGet Rating) will announce sales of $32.52 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The lowest sales estimate is $31.88 million and the highest is $33.10 million. Aerie Pharmaceuticals reported sales of $27.19 million in the same quarter last year, which would suggest a positive year over year growth rate of 19.6%. The firm is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Aerie Pharmaceuticals will report full year sales of $135.36 million for the current fiscal year, with estimates ranging from $132.32 million to $140.33 million. For the next year, analysts anticipate that the company will report sales of $179.07 million, with estimates ranging from $155.30 million to $200.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERIGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.01). During the same period in the previous year, the business earned ($0.72) earnings per share.

Several analysts have commented on AERI shares. StockNews.com started coverage on shares of Aerie Pharmaceuticals in a research report on Thursday, March 31st. They set a “hold” rating for the company. Cowen dropped their target price on shares of Aerie Pharmaceuticals from $30.00 to $25.00 in a research report on Friday, February 25th. Needham & Company LLC dropped their target price on shares of Aerie Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Finally, Citigroup dropped their target price on shares of Aerie Pharmaceuticals from $23.00 to $13.00 in a research report on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.52.

Shares of Aerie Pharmaceuticals stock traded up $0.36 on Monday, hitting $6.81. 512,084 shares of the company’s stock traded hands, compared to its average volume of 520,899. The firm’s 50-day moving average price is $8.20 and its two-hundred day moving average price is $8.40. The stock has a market capitalization of $331.10 million, a PE ratio of -4.54 and a beta of 0.74. Aerie Pharmaceuticals has a one year low of $5.46 and a one year high of $19.26.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AERI. Millennium Management LLC increased its holdings in Aerie Pharmaceuticals by 696.2% during the 4th quarter. Millennium Management LLC now owns 1,017,665 shares of the company’s stock worth $7,144,000 after purchasing an additional 889,851 shares in the last quarter. William Blair Investment Management LLC increased its holdings in Aerie Pharmaceuticals by 31.6% during the 3rd quarter. William Blair Investment Management LLC now owns 2,877,149 shares of the company’s stock worth $32,799,000 after purchasing an additional 690,649 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in Aerie Pharmaceuticals by 75.7% during the 1st quarter. Levin Capital Strategies L.P. now owns 1,435,876 shares of the company’s stock worth $13,066,000 after purchasing an additional 618,499 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Aerie Pharmaceuticals by 39.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,678,609 shares of the company’s stock worth $15,275,000 after buying an additional 475,017 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Aerie Pharmaceuticals in the 4th quarter valued at about $3,201,000.

About Aerie Pharmaceuticals (Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.

Further Reading

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.